Trial Profile

A phase I study of RVU120 with everolimus in children with recurrent or progressive group 3 or 4 medulloblastoma

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 31 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 Oct 2025 New trial record
09 Sep 2025 According to a Ryvu Therapeutics media release, at IPCZD, the study is led by Prof.Bozenna Dembowska-Baginska with the Department of Pediatric Oncology team, in collaboration with Prof.Wieslawa Grajkowska and Prof.Joanna Trubicka. The first drug shipment is expected in Q2 2026, with the MEDWAY project scheduled from July 2025 to June 2033. Company will collaborate closely with the IPCZD team throughout the study.
09 Sep 2025 According to a Ryvu Therapeutics media release, the company announced its involvement in the MEDWAY project, executed by the Children's Memorial Health Institute (IPCZD), supporting a non-commercial phase I study evaluating RVU120 in combination with everolimus in children with recurrent or progressive Group 3 or 4 medulloblastoma.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com